title: Transdermal innovations in diabetes management.
abstract: Diabetes mellitus, an endocrine disorder affecting glucose metabolism, has been crippling mankind for the past two centuries. Despite the advancements in the understanding pertaining to its pathogenesis and treatment, the currently available therapeutic options are far from satisfactory. The growing diabetic population increases the gravity of the situation. The shortcomings of the conventional drug delivery systems necessitate the need to delve into other routes. On account of its merits over other routes, the transdermal approach has drawn the interest of the researchers around the world. The transdermal drug delivery systems are aimed to achieve therapeutic concentrations of the drug through skin. These systems are designed so that the drug can be delivered at a pre-determined and controlled rate. This makes it particularly conducive to treat chronic disorders like diabetes. Correspondingly, the adverse effects and inconvenience concomitant with oral and parentral route are circumvented. This article attempts to outline the development of transdermal drug delivery systems to optimize diabetes pharmacotherapy. It not only covers the transdermal approaches adopted to fine-tune insulin delivery, but also, discusses various transdermal drug delivery systems fabricated to improve the therapeutic performance of oral hypoglycaemic agents. Such formulations include the advanced drug delivery systems, namely, transferosomal gels, microemulsions, self-dissolving micropiles, nanoparticles, insulin pumps, biphasic lipid systems, calcium carbonate nanoparticles, lecithin nanoparticles; physical techniques such as iontophoresis and microneedles and, drugs formulated as transdermal patches. In addition to this, the authors have also shed light on the future prospects and patented and commercial formulations of antidiabetic agents.
authors.forename: Rekha
authors.initials: R
authors.lastname: Rao
authors.forename: Sheefali
authors.initials: S
authors.lastname: Mahant
authors.forename: Lovely
authors.initials: L
authors.lastname: Chhabra
authors.affiliation: Faculty of Pharmaceutical Sciences, M.D. University, Rohtak, 124-001, India. sn_mdu@rediffmail.com.
authors.forename: Sanju
authors.initials: S
authors.lastname: Nanda
mesh_terms: D000279:Administration, Cutaneous; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000266:history / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000266:history / Q000378:metabolism; D016503:Drug Delivery Systems / Q000266:history / Q000379:methods*; D004586:Electrophoresis; D018274:Electroporation; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000266:history / Q000494:pharmacology; D007478:Iontophoresis; D053758:Nanoparticles; D004364:Pharmaceutical Preparations / Q000266:history; D012869:Skin Absorption / Q000187:drug effects*; D016896:Treatment Outcome
chemical_list: D007004:Hypoglycemic Agents; D004364:Pharmaceutical Preparations